Abbey, Megha
Vedadi, Masoud
2018-06-20
<p>The pH range used earlier was expanded for further optimization to check if the activity could improve.</p>
<p> </p>
<p><strong>Note: </strong>1. In the assay buffer, BSA conc. is 0.5 mg/ml (instead of 0.5%).</p>
<p> 2. In the 7.5 ul developer solution, 40 uM of TSA (Trichostatin A) is also included.</p>
The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
https://doi.org/10.5281/zenodo.1293893
oai:zenodo.org:1293893
Zenodo
https://zenodo.org/communities/sgc-opennotebook
https://zenodo.org/communities/openlabnotebooks
https://doi.org/10.5281/zenodo.1293892
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
HDAC11
buffer optimization
HDAC11 substrate
HDAC11 high-throughput
Histone deacetylase
HDAC 11
HDAC
Histone decaetylase 11
HDAC11 activity
HDAC11 activity assay
HDAC assay optimization
The process of HDAC11 Assay Development: Buffer optimization again
info:eu-repo/semantics/other